Corrigendum to “Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables” [Int. J. Mycobacteriol. 5(1) 2016 1-6]. Go to Publication You Might Also Like Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. July 6, 2009 Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective. April 8, 2010 Normal chest radiographs in sputum culture-positive pulmonary tuberculosis. January 13, 2009 Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015 APACHE II expected outcome calculations are subject to inter-observer variation. October 10, 1990
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. July 6, 2009
Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. March 2, 2015